Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;109(4):918-927.
doi: 10.1002/cpt.2186. Epub 2021 Feb 28.

The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy

Erin M B Scholz  1 , Angela D M Kashuba  1   2
Affiliations
Review

The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy

Erin M B Scholz et al. Clin Pharmacol Ther. 2021 Apr.

Abstract

Despite advances in treatment, finding a cure for HIV remains a top priority. Chronic HIV infection is associated with increased risk of comorbidities, such as diabetes and cardiovascular disease. Additionally, people living with HIV must remain adherent to daily antiretroviral therapy, because lapses in medication adherence can lead to viral rebound and disease progression. Viral recrudescence occurs from cellular reservoirs in lymphoid tissues. In particular, lymph nodes are central to the pathology of HIV due to their unique architecture and compartmentalization of immune cells. Understanding how antiretrovirals (ARVs) penetrate lymph nodes may explain why these tissues are maintained as HIV reservoirs, and how they contribute to viral rebound upon treatment interruption. In this report, we review (i) the physiology of the lymph nodes and their function as part of the immune and lymphatic systems, (ii) the pathogenesis and outcomes of HIV infection in lymph nodes, and (iii) ARV concentrations and distribution in lymph nodes, and the relationship between ARVs and HIV in this important reservoir.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest statement: All authors declared no competing interests for this work.

Figures

Figure 1:
Figure 1:
A) An overview of the structure and flow (arrows) in a lymph node. The capsule (1) is the outmost later of endothelial cells. Lymphatic fluid flows into the node through the afferent (2) lymphatics, around the node through the subcapsular sinus (3), then between each lymph node lobule (dashed region, expanded in B) through the transverse sinuses (4). From the subcapsular sinus fluid can diffuse into the cortex (5), and from the transverse sinuses into the paracortex (6). Finally, lymphatic fluid collects in the medulla (7), and makes its way out of the node through the efferent lymphatics (8) in the hilus (9). B) An overview of the structure and cellular organization of a lymph node lobule. The cortex (1) is the outermost region containing follicles (2), which are made up primarily of B cells and FDCs. The next region is the paracortex (3), containing primarily T cells and DCs, as well as the HEVs (4). Lastly, the medulla (5) is an area of lymph flow and cell trafficking, and its appearance is characterized by a maze-like appearance of medullary cords (dark green) sinuses (light green). Throughout the lymph node the FRC network (gray lines) gives the tissue shape and structure.
Figure 2:
Figure 2:
An overview of expected A) HIV and B) ARV distribution in the lymph node. A) The red color gradient represents variability in HIV distribution throughout the lymph node, with more virus located in dark regions and less virus in lighter regions. Higher HIV concentrations are expected the the B cells follicles, where virions are trapped on FDCs, and in the T cell zone in infected CD4+ T cells. B) The green color gradient represents changes in drug distribution throughout the lymph node, with higher drug concentrations in dark regions and lower drug concentrations in lighter regions. Increased ARV penetration is expected around the subcapsular and transverse sinuses, and surrounding HEVs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cihlar T & Fordyce M Current status and prospects of HIV treatment. Curr Opin Virol 18, 50–56 (2016). - PubMed
    1. Guaraldi G et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin. Infect. Dis. 53, 1120–1126 (2011). - PubMed
    1. Guaraldi G et al. Cost of noninfectious comorbidities in patients with HIV. Clinicoecon. Outcomes Res. 5, 481–488 (2013). - PMC - PubMed
    1. Duffau P et al. Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. AIDS 32, 1651–1660 (2018). - PubMed
    1. Li JZ et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343–353 (2016). - PMC - PubMed

Publication types

MeSH terms

Substances